Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: A comprehensive meta-analysis of efficacy and safety outcomes in short-term trials

CNS Spectrums

Volumn 21, Issue 5, 2016, Pages 403-418

  Solmi, Marco ^a,b   Veronese, Nicola ^a,b   Zaninotto, Leonardo ^b,c   Van Der Loos, Marc L M ^d   Gao, Keming ^e   Schaffer, Ayal ^f   Reis, Catherine ^f   Normann, Claus ^g   Anghelescu, Ion George ^h   Correll, Christoph U ^b,i,j,k,l  

^a UNIVERSITY OF PADOVA   (Italy)

^b Institute for Clinical Research and Education in Medicine   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ISALA HOSPITAL   (Netherlands)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF FREIBURG   (Germany)

^h Dr Kurt Fontheim's Hospital for Mental Health   (Germany)

ⁱ ZUCKER HILLSIDE HOSPITAL   (United States)

^j DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^k FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Bipolar depression; bipolar disorder; lamotrigine; major depressive disorder; trials; unipolar depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; INOSITOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; DRUG COMBINATION; NEUROLEPTIC AGENT; TRANQUILIZER; TRIAZINE DERIVATIVE; VITAMIN B COMPLEX;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MANIA; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; BIPOLAR DISORDER; COMPARATIVE STUDY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATIONS; FLUOXETINE; HUMANS; INOSITOL; LITHIUM; TRIAZINES; VITAMIN B COMPLEX;

EID: 84989914236     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852916000523     Document Type: Article

References (74)

1. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004; 65(11): 1499-1504
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-Term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59(6): 530-537
3. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-Term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60(3): 261-269
4. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. The societal cost of bipolar disorder in Sweden. Soc Psychiatry Psychiatr Epidemiol. 2013; 48(10): 1601-1610
5. Miller S, Dell?Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014; 169(Suppl 1): S3-S11
6. Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J Affect Disord. 2013; 149(1-3): 46-55
7. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117(Suppl 1): S26-S43
8. National Collaborating Centre for Mental Health (UK). Updated ed. Leicester, UK: British Psychological Society; 2010
9. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170 (11): 1249-1262
10. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15(1): 1-44
11. Liu CC, Liang KY, Liao SC. Antidepressant-Associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. J Psychopharmacol. 2009; 23(2): 220-222
12. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006; 189(2): 124-131
13. Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014; 171(10): 1067-1073
14. Kim SJ, Lee YJ, Lee YJ, Cho SJ. Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression. J Affect Disord. 2014; 157: 33-40
15. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013; 27(7): 515-529
16. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010; 18(3): 143-157
17. Bennabi D, Aouizerate B, El-Hage W, et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015; 171: 137-141
18. Cardoso De Almeida JR, Phillips ML. Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives. Biol Psychiatry. 2013; 73(2): 111-118
19. Parker G, McCraw S, Hadzi-Pavlovic D, Hong M, Barrett M. Bipolar depression: prototypically melancholic in its clinical features. J Affect Disord. 2013; 147(1-3): 331-337
20. Rastelli CP, Cheng Y, Weingarden J, Frank E, Swartz HA. Differences between unipolar depression and bipolar II depression in women. J Affect Disord. 2013; 150(3): 1120-1124
21. Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013; 74(7): 675-684
22. Desarkar P, Sinha VK. Lamotrigine-induced severe manic switch. Aust N Z J Psychiatry. 2006; 40(8): 718
23. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006; 163(2): 232-239
24. Ketter TA, Miller S, Dell'Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord. 2014; 169(Suppl 1): S24-S33
25. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-Treatments meta-Analysis. Acta Psychiatr Scand. 2014; 130(6): 452-469
26. Tundo A, De Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: evidences and personal experience. World J Psychiatry. 2015; 5(3): 330-341
27. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-Analysis and metaregression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1): 4-9
28. Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-Analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014; 47(2): 43-52
29. Vieta E, Locklear J, Günther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol. 2010; 30(5): 579-590
30. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med. 2009; 151(4): 264-269
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382-389
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr. 1960; 23: 56-62
33. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6(4): 278-296
34. Higgins J, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration?s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928
35. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-188
36. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ. 2003; 327(7414): 557-560
37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-634
38. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4): 1088-1101
39. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo- controlled, double-blind study. J Clin Psychiatry. 2002; 63(4): 337-344
40. Lieb K, Walden J, Grunze H, Fiebich BL, Berger M, Normann C. Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry. 2004; 37(5): 238-239
41. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006; 67(7): 1025-1033
42. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009; 12(6): 773-782
43. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999; 60(2): 79-88
44. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008; 10(2): 323-333
45. Brown ES, Sunderajan P, Hu LT, Sowell SM, Carmody TJ. A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology. 2012; 37(11): 2347-2354
46. Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol. 2007; 22(3): 179-182
47. Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord. 2008; 111(2-3): 334-343
48. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatmentresistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006; 163(2): 210-216
49. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007; 115(5): 360-365
50. Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry. 2011; 72(10): 1405-1412
51. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebocontrolled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003; 64(4): 403-407
52. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 2008; 10(3): 187-190
53. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord. 2006; 96(1-2): 95-99
54. Kemp DE, Gao K, Fein EB, Chan, et al. Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a doubleblind, placebo-controlled trial in rapid-cycling bipolar disorder. Bipolar Disord. 2012; 14(7): 780-789
55. Van Der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(2): 223-231
56. Wang Z, Gao K, Kemp DE, et al. Lamotrigine adjunctive therapy to lithiumand divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. Psychopharmacol Bull. 2010; 43(4): 5-21
57. Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. Bipolar Disord. 2002; 4(5): 323-327
58. Gao K, Yuan C, Wu R, et al. Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. Neurosci Bull. 2015; 31(5): 572-588
59. Carvalho AF, Quevedo J, McIntyre RS, et al. Treatment implications of predominant polarity and the polarity index: a comprehensive review. Int J Neuropsychopharmacol. 2014; 18(2): pyu079
60. Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord. 2012; 14(Suppl 2): 51-65
61. Lin CY, Tsai GE, Wang HS, et al. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study. J Clin Psychiatry. 2014; 75(9): e924-e931
62. Parker G, McCraw S. The ?disconnect? between initial judgments of lamotrigine vs. its real-world effectiveness in managing bipolar disorder. A tale with wider ramifications. Acta Psychiatr Scand. 2015; 132(5): 345-354
63. Bowden CL, Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin Pharmacother. 2012; 13(17): 2565-2571
64. Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect?. Data from randomized clinical trials. CNS Neurosci Ther. 2011; 17(3): 167-177
65. Rihmer Z, Gonda X, Kalman J. [Treatment of bipolar disorder with lamotrigine-relapse rate and suicidal behaviour during 6 month follow-up]. Neuropsychopharmacol Hung. 2015; 17(1): 7-13
66. Bhowmik D, Aparasu RR, Rajan SS, Sherer JT, Ochoa-Perez M, ChenH. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014; 24(10): 551-561
67. Park KJ, Shon S, Lee JH, Joo Y, Youngstrom EA, Kim HW. Antidepressant-emergent mood switch in Korean adolescents with mood disorder. Clin Neuropharmacol. 2014; 37(6): 177-185
68. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011; 21(6): 517-535
69. Zhang JP, Gallego JA, Robinson DG, Malhotra AQ, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. firstgeneration antipsychotics in first-episode psychosis: a systematic review andmeta-Analysis. Int J Neuropsychopharmacol. 2013; 16(6): 1205-1218
70. Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015; 14(1): 73-96
71. Blaszczyk B, Lason W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015; 67(3): 426-434
72. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002; 63(11): 1012-1019
73. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- And third-generation antiepileptic drugs. Expert Rev Neurother. 2010; 10(1): 119-140
74. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003; 2: 347-356